Nephros upgraded to Speculative Buy from Hold at Benchmark

Benchmark upgraded Nephros to Speculative Buy from Hold with a $5 price target after the company reported “solid” results for Q4 and 2023 as a whole. The firm, which forecasts that Nephros will post revenues of $17.1M, up 20% year-over-year in FY24, sees a “positive outlook and quarterly comparisons going forward.”